{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}],"title":"TRA100773 Responders >= 50 Gi/L in EXTEND, n=51"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47"}]}],"title":"TRA100773 >=50 Gi/L and 2 x BL in EXTEND, n=51"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}],"title":"TRA100773 Responders >= 30 Gi/L in EXTEND, n=51"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54"}]}],"title":"RAISE Responders >= 50 Gi/L in EXTEND, n=59"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"}]}],"title":"RAISE >= 50 Gi/L and 2 x BL in EXTEND, n=59"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55"}]}],"title":"RAISE Responders >= 30 Gi/L in EXTEND, n=51"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}],"title":"REPEAT Responders >= 50 Gi/L in EXTEND, n=36"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}],"title":"REPEAT>= 50 Gi/L and 2 x BL in EXTEND, n=36"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}],"title":"REPEAT Responders >= 30 Gi/L in EXTEND, n=36"}],"denoms":[{"counts":[{"groupId":"OG000","value":"302"}],"units":"Participants"}],"description":"Responder in TRA100773: Platelet count 50 Gi/L and 2 x baseline (BL) at last on-treatment assessment. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline (BL), 50 Gi/L, and 30 Gi/L at any time. Responder in RAISE: Platelet count 50GI/L and 2 x baseline at Week 6 assessment. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline, 50 Gi/L, and 30 Gi/L at any time. Responder in REPEAT: Platelet count 50 GI/L and 2 x baseline (BL) at Week 6 assessment in Cycle 1. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline (BL) 50 Gi/L, and 30 Gi/L at any time.","groups":[{"description":"Open-label eltrombopag was supplied in 25, 50, 75 mg tablets. All subjects started at 50mg once daily and dose was increased or decreased based on platelet count (target range 50-200Gi/L). Alternate days and interruption of dosing was permitted to maintain target range of platelet count. Doses could range from 25 to 75mg. Subjects could remain on treatment up to 2 years.","id":"OG000","title":"Eltrombopag"}],"paramType":"NUMBER","populationDescription":"ITT","reportingStatus":"POSTED","timeFrame":"Baseline up to 2 years","title":"Number of Subjects Who Responded to Eltrombopag in a Previous Study and Who Respond to Retreatment With a Rise in Platelet Count to Either ≥ 50,000/µL or ≥30,000/µL","type":"SECONDARY","unitOfMeasure":"Participants"}